Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Clinically speaking, Roche/Genentech’s injectable Lucentis (ranibizumab) looks well-positioned for a role in diabetic macular edema after the full release of Phase III trial data.